HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. (Q51321425)
Jump to navigation
Jump to search
scientific article published on 4 June 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. |
scientific article published on 4 June 2014 |
Statements
1 reference
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. (English)
1 reference
Bo Ahrén
1 reference
Susan L Johnson
1 reference
Murray Stewart
1 reference
Deborah T Cirkel
1 reference
Fred Yang
1 reference
Caroline Perry
1 reference
Mark N Feinglos
1 reference
HARMONY 3 Study Group
1 reference
4 June 2014
1 reference
1 reference
37
1 reference
2141-2148
1 reference
8
1 reference
Identifiers
1 reference
1 reference